References
- DartJEye disease at a community health centreBMJ1986293147714803099921
- McDonnellPHow do general practitioners manage eye disease in the communityBr J Opthalmol199872733376
- SheikhAHurwitzBTopical antibiotics for acute bacterial conjunctivitis: a systematic reviewBr J Gen Pract20015147347711407054
- SheikhAHurwitzBAntibiotics versus placebo for acute bacterial conjunctivitisCochrane Database Syst Rev20062CD00121116625540
- SheikhAHurwitzBTopical antibiotics for acute bacterial conjunctivitis: Cochrane systematic review and meta-analysis updateBr J Gen Pract20055596296416378567
- RosePHarndenABrueggemannAPereraSheikh ACrookDChloramphenicol treatment for acute infective conjunctivitis in children in primary care: a randomized double-blind placebo-controlled trialLancet2005366374315993231
- WestSAzithromycin for control of trachomaCommunity Eye Health199912555617492006
- EverittHLittlePHow do GPs diagnose and manage acute infective conjunctivitis? A GP surveyFam Pract1999125556
- PerryHDonnenfeldDIssues in the use of preservative-free topicalsManag Care200312 Suppl394214723113
- FriedlaenderMHProtzkoEClinical development of 1% azithromycin in DuraSite, a topical azalide anti-infective for ocular surface therapyClin Ophthalmol20071131019668461
- BuznachNDaganRGreenbergDClinical and bacterial characteristics of acute bacterial conjunctivitis in children in the antibiotic resistance eraPediatr Infect Dis J20052482382816148850
- FriedlaenderMHProtzkoEResponse to correspondence from Lichtenstein and Granet Re: Fluoroquinolones compared to 1% azithromycin in DuraSite for bacterial conjunctivitisClin Ophthalmol20082124224419668415
- McCrackenGMicrobiologic activity of the newer macrolide antibioticsPediatr Infect Dis J1997164324379109155
- OhnsmanCRitterbandDO’BrienTGirgisDKabatAComparison of azithromycin and moxifloxacin against bacterial isolates causing conjunctivitisCurr Med Res Opin2007232241224917688706
- GigliottiFHendleyJMorganJMichaelsRDickensMLohrJEfficacy of topical antibiotic therapy in acute conjunctivitis in childrenJ Pediatr19841046236266323667
- LeibowitzHAntibacterial effectiveness of ciprofloxacin 0.3% ophthalmic solution in the treatment of bacterial conjunctivitisAm J Ophthalmol199111229533S
- MillerIWittreichHVogelRCookTThe safety and efficacy of topical norfloxacin compared with placebo in the treatment of acute bacterial conjunctivitisEur J Ophthlamol1992258266
- RietveldRTietGdBindelsPBinkDSloosJWeertHVThe treatment of acute infectious conjunctivitis with fusidic acid: a randomized controlled trialBr J Gen Pract200555992493016378561
- EverittHLittlePSmithPA randomized controlled trial of management strategies for acute infective conjunctivitis in general practiceBMJ200633332116847013
- LeiboviciLLievreMMedicalization: peering from the insideBMJ200232486611950721
- SheikhADelayed prescribing of antibiotics is an effective strategy in managing acute conjunctivitisJ Pediatr2007150114115
- LittlePGouldCWilliamsonIWarnerGGanrleyMKinmonthAReattendance and complications in a randomized trial of prescribing strategies for sore throat: the medicalizing effect of prescribing antibioticsBMJ1997314177182
- AbelsonMHellerWShapieroAclinical cure of bacterial conjunctivitis with azithromycin1%: vehicle-controlled double-masked clinical trialAm J Ophthalmol200814595996518374301
- AbelsonMHellerWEfficacy of azithromycin 1% eye drops vs vehicle as first line therapy for bacterial conjunctivitisUnpublished study the Cochrane Register of Controlled Trials (CENTRAL)2006ID CN00634804.
- AbelsonMProtzkoEShapieroAGarces–SoldanaABowmanLA randomized trial assessing the clinical efficacy and microbial eradication of 1% azithromycin ophthalmic solution vs tobramycin in adult and pediatric subjects with bacterial conjunctivitisClin Ophthalmol2007117718219668507
- HellerWAbelsonMGroupTASSafety and tolerabiltiy of azithromycin 1% eye drops as anti-infective therapy for bacteria conjunctivitisUnpublished study for the Cochrane Register of Controlled Trials (CENTRAL)Study ID CN 00634521.
- ProtzkoEBowmanLAbelsonMShapieroAGroup TACSPhase 3 safety comparisons for 1% azithromycin in polymeric muco-adhesive eye drops versus 0.3% tobramycin eye drops for bacterial conjunctivitisInvest Ophthalmol Vis Sci2007483425342917652708
- GranetDLichtenstanSJOnofneyBKatzJAAn assessment of the tolerability of moxifloxacin 0.5% compared to azithromycin 1.0% in durasiteClin Ophthalmol2007113313919668502
- BowmanLSiEPangJArchibadRFriedlaenderMDevelopment of a topical polymeric mucoadhesive ocular delivery system for azithromycinJ Ocul Pharmacol Ther2009213313919284320
- SiPCBowmanLHosseiniKOcular pharmacokinetics of Azasite Xtra – 2% azithromycin formulated in a Durasite delivery systemCurr Eye Res20093448549119899983
- DorfmanMWagnerRJamisonTBellBStromanDWThe pharmacodynamic properties of azithromycin in a kinetics of kill model and implications for bacterial conjunctivitis treatmentAdv Ther20082520821718369536
- LichtensteinSGranetDFluoroquinolones compared to 1% azithromycin in durasite for bacterial conjunctivitisClin Ophthalmol2007151952519668531
- WinfieldAJessimanDSilliamsAA study of the causes of non-compliance by patients prescribed eyedropsBr J Opthalmol199074477480
- JampelHSchwartzGRobinAPatient preference for eye drop characteristics: a willingness to pay analysisArch Ophthalmol200312154054612695251
- FDAPatient information leaflet NDA 50-810. Revised 5/2007. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search [Label Approval History] Accessed December 7, 2009.